[144] Cellebrite DI Ltd. Warrants SEC Filing

Rhea-AI Filing Summary

Form 144 filed for CLBTW: proposed sale of 15,995 ordinary shares on Nasdaq. The shares were acquired when 31,728 restricted share units vested under an S-8 plan on 08/15/2025 and were paid as employee compensation. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and shows an aggregate market value of $249,522.00 for the proposed sale.

The filer previously sold 7,384 shares on 05/19/2025 for gross proceeds of $128,555.44. The filing includes the seller's representation that they are not aware of undisclosed material adverse information about the issuer.

Positive

• Securities to be sold arise from vested RSUs, indicating compensation-originated liquidity rather than external transaction
• Broker identified (Morgan Stanley Smith Barney LLC), showing an institutional execution path
• Prior sale disclosed (7,384 shares on 05/19/2025 for $128,555.44), meeting Rule 144 transparency requirements

Negative

• No material adverse information disclosed is asserted by the filer, but the filing contains no operational or financial context for investors
• Large outstanding share count (244,766,996) makes the proposed sale immaterial to capital structure; limited investor impact

Insights

Securities Analyst

TL;DR: Insider plans to sell vested RSU shares soon; transaction size is modest relative to outstanding shares.

The filing documents a proposed sale of 15,995 ordinary shares following RSU vesting on 08/15/2025, placed with Morgan Stanley Smith Barney LLC and valued at $249,522.00. Total shares outstanding are reported as 244,766,996, so the proposed sale represents a de minimis fraction of outstanding equity. A prior sale of 7,384 shares on 05/19/2025 realized $128,555.44 in gross proceeds. Information is transactional and routine under Rule 144; there are no disclosures of material operational or financial changes in this notice.

Corporate Governance Expert

TL;DR: Routine insider liquidity event from vested RSUs; includes standard certification about material information.

The report shows the securities were acquired by vesting of RSUs under an S-8 plan and will be sold through an institutional broker. The filer executed a prior sale within the past three months, which is disclosed here as required. The document contains the customary signature representation that no undisclosed material adverse information is known. No governance actions, executive changes, or regulatory events are disclosed in this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares, par value NIS 0.00001	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Floor New York NY 10004	15995	249522.00	244766996	08/18/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares, par value NIS 0.00001	08/15/2025	Restricted Share Units Vested Under an Issuer S-8 Registered Plan	Cellebrite DI Ltd.			31728	08/15/2025	Employee compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Marcus Jewell 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	Ordinary shares, par value NIS 0.00001	05/19/2025	7384	128555.44

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for CLBTW report?

This Form 144 reports a proposed sale of 15,995 ordinary shares of CLBTW to be executed through Morgan Stanley Smith Barney LLC with an aggregate market value of $249,522.00.

When were the shares acquired that are being sold?

The shares were acquired on 08/15/2025 when 31,728 restricted share units vested under an issuer S-8 registered plan; payment was employee compensation.

Has the filer sold shares of CLBTW recently?

Yes. The filer sold 7,384 shares on 05/19/2025 for gross proceeds of $128,555.44 within the past three months.

How many CLBTW shares are outstanding according to the filing?

The filing reports 244,766,996 shares outstanding.

Which exchange will the proposed sale be on?

The proposed sale is listed for execution on Nasdaq.